ARAY
Accuray Incorporated
ARAY lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ARAY Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Weak |
ARAY's revenue, profitability, cash flow and balance sheet are all currently under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ARAY PE Valuation
ARAY has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ARAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect ARAY's losses to shrink, with revenue holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ARAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$6.00 | +$0.40 |
| Q2 2026 | -$16.00 | -$15.20 |
| Q1 2026 | -$14.80 | -$14.80 |
| Q4 2025 | -$11.60 | -$9.60 |
| Q3 2025 | -$6.40 | +$0.40 |
| Q2 2025 | -$0.80 | +$5.60 |
| Q1 2025 | $0.00 | +$8.80 |
| Q4 2024 | -$2.00 | +$4.00 |
ARAY has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ARAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $86.5M | -7.9% |
| Q2 2026 | $100.9M | -21% |
| Q1 2026 | $104.8M | -7.4% |
| Q4 2025 | $102.2M | -12% |
| Q3 2025 | $93.9M | -7.5% |
| Q2 2025 | $127.5M | -5% |
| Q1 2025 | $113.2M | +12% |
| Q4 2024 | $116.2M | +8.3% |
ARAY's revenue has slid since its 2024 peak: $87M last quarter, down 7.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -42% | -30 points |
| Q2 2026 | 5.5% | +2.1 points |
| Q1 2026 | -8.7% | -9.6 points |
| Q4 2025 | -11% | -15 points |
| Q3 2025 | -12% | -9.9 points |
| Q2 2025 | 3.3% | -1.8 points |
| Q1 2025 | 0.9% | +5.4 points |
| Q4 2024 | 4% | +7.8 points |
ARAY's operating margin was −42% last quarter, down 30 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ARAY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ARAY on profitability, with a higher operating margin.
ARAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.9M | -138% |
| Q2 2026 | $2M | +$13M |
| Q1 2026 | -$6.1M | -136% |
| Q4 2025 | -$19M | -2151% |
| Q3 2025 | $10.3M | +$18.7M |
| Q2 2025 | -$11M | -217% |
| Q1 2025 | $17.1M | +$26M |
| Q4 2024 | $927K | +$7.3M |
ARAY's free cash flow was −$27M over the past year, against $17M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ARAY on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +14% | +416K shares |
| 1 year | +35% | +911K shares |
| 3 years | +43% | +1M shares |
| 5 years | +50% | +1.2M shares |
| Available history | +54% | +1.2M shares |
ARAY has 3M diluted shares, up 35% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ARAY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ARAY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 17.8x | High |
| Q2 2025 | 6.6x | High |
| Q1 2025 | 6.3x | High |
| Q4 2024 | 11.1x | High |
| Q3 2024 | 52.6x | High |
| Q2 2024 | 17.4x | High |
| Q4 2023 | 21.3x | High |
| Q3 2023 | 9.3x | High |
ARAY's net debt is about 18 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ARAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.4 | Oversold |
| Stochastic | 3.2 | Oversold |
ARAY's weekly RSI is 26 (oversold) and its Stochastic is 3 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ARAY PE vs Healthcare Sector
| Metric | ARAY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ARAY has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ARAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.69 | 54% below |
| 20 week MA | $8.94 | 66% below |
| 50 week MA | $16.9 | 82% below |
| 100 week MA | $40.9 | 92% below |
| 200 week MA | $72.4 | 96% below |
ARAY is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ARAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $112.8 | $177.2 | +57% |
| 2021 | $177.2 | $195.6 | +10% |
| 2022 | $195.6 | $79.2 | -60% |
| 2023 | $79.2 | $113.2 | +43% |
| 2024 | $113.2 | $73.2 | -35% |
| 2025 | $73.2 | $33.0 | -55% |
| 2026 YTD | $33.0 | $3.08 | -91% |
ARAY has finished lower in three of the last six years. It's down 91% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ARAY on returns for 2026, with the stronger performance.